Based on the correlation between the copy number losses of PTEN, FAS, PAPSS2 and PSA recurrence and with the current quest for an improved biomarker, it is recommended that the molecular function and translational implication of PTEN, FAS, and PAPSS2 loss in prostate cancer are further investigated. The gene discussed is PTEN; the disease is prostate carcinoma.